Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- US FDA Approves 1st Generic Versions of Zyprexa, Eli Lilly’s Top Mainstay Product
October 26, 2011
- Subcommittee to Recommend Use of Most-recent 3-year Averages in Drug Cost Calculation
October 26, 2011
- Chuikyo Subcommittee Approves Revision of Foreign Price Adjustment Rule
October 26, 2011
- Korosho to Take Stricter Look at Companies’ Market Size Forecasts
October 26, 2011
- JMA, JPA Oppose Increase in Patients’ Copayments for OTC-like Drugs
October 26, 2011
- TPP Could Have Major Impact on NHI Price System: Ms Weatherall of University of Queensland
October 26, 2011
- Patent Office to Revise Rules for Granting Patent Extensions
October 25, 2011
- Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 25, 2011
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 25, 2011
- EMA Confirms Usefulness of Pioglitazone-Containing Medicines as 2nd, 3rd Line Treatment Options: Takeda
October 24, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 24, 2011
- Korosho Receives 270 Requests for Development of Unapproved Drugs, Indications in 2nd Round
October 24, 2011
- Groups of Care Providers, Patients Against Creating Compensation System for Injury from Anticancer Drugs
October 22, 2011
- Drug Discovery Support Agency Will Not Compete with Private Sector: Mr Tsuchiya
October 21, 2011
- CSIMC Recommended Approval for Reimbursement on Piecework for 2 High-Priced Drugs
October 21, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 21, 2011
- MHLW to Review Premium System Placing Priority on Premium for Pediatric Use
October 20, 2011
- Mr Kobayashi of Chuikyo Insists on NHI Price Reductions for New Generics
October 20, 2011
- MHLW Subcommittee Agrees on Access System for Domestically Unapproved Drugs
October 20, 2011
- MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…